Advance pre-clinical development of DNDI-6166 (CC6166) as a macrofilaricide candidate for filarial diseases
current phase of drug development
updated 16 Feb 2023
DNDi and partners have accessed libraries of pharmaceutical compounds to identify new anthelmintic molecules active against Onchocerca species, with the aim of developing a drug candidate for filarial indications. Following the identification of several hits, collaborative hit-to-lead and lead optimization programmes were initiated with Celgene and AbbVie. DNDi provided biological resources, expertise, and the target candidate profile to select the best candidates. In 2019, DNDI-6166 (previously known as CC6166) was nominated as pre-clinical candidate and selected for further development by DNDi and Bristol-Myers Squibb (formerly Celgene). In late 2020, DNDi absorbed the project in its entirety.
Get our latest news, personal stories, research articles, and job opportunities.